| Literature DB >> 31733679 |
Jean-Louis Vincent1, Elisa Bogossian2, Marco Menozzi2.
Abstract
Numerous compounds have been tested as potential biomarkers for multiple possible applications within intensive care medicine but none is or will ever be sufficiently specific or sensitive for the heterogeneous syndromes of critical illness. New technology and access to huge patient databases are providing new biomarker options and the focus is shifting to combinations of several or multiple biomarkers rather than the single markers that research has concentrated on in the past. Biomarkers will increasingly be used as part of routine clinical practice in the future, complementing clinical examination and physician expertise to provide accurate disease diagnosis, prediction of complications, personalized treatment guidance, and prognosis.Entities:
Keywords: Biomarker panels; Phenotypes; Precision medicine; Sensitivity; Specificity
Mesh:
Substances:
Year: 2020 PMID: 31733679 DOI: 10.1016/j.ccc.2019.08.014
Source DB: PubMed Journal: Crit Care Clin ISSN: 0749-0704 Impact factor: 3.598